An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 37
- 试验地点
- 26
- 主要终点
- Number of participants with clinically significant changes in Eastern Co-operative Oncology Group (ECOG) performance status
研究概览
简要总结
This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592, NCT03308942, NCT02657889) that has fulfilled the requirements for the primary objective.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
盲法说明
This will be an open-label study.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant is able to understand the study procedures and agrees to participate in the study by providing written informed consent.
- •Participant is willing and able to comply with scheduled visits, treatment plans, and any other study procedures.
- •Participant is currently receiving treatment with niraparib (as monotherapy or in combination) in a GlaxoSmithKline/TESARO-sponsored study that has fulfilled the requirements for the primary objective.
- •Participant is currently benefiting from treatment with niraparib as assessed by the Investigator according to the parent study protocol requirements.
- •Participants of childbearing potential who are sexually active and their partners must agree to the use of an effective form of contraception throughout their participation during study treatment through 180 days after last dose of study drug.
排除标准
- •Participant has been permanently discontinued from niraparib treatment in the parent study for any reason.
- •Participant currently has unresolved toxicities for which niraparib dosing has been interrupted in the parent study. Participants meeting all other eligibility criteria may be enrolled once toxicities have resolved to allow niraparib treatment to resume.
- •Participant is pregnant or is expecting to conceive children while receiving study drug or for up to 180 days after the last dose of study drug. Participant is breastfeeding or is expecting to breastfeed within 30 days of receiving the final dose of study drug (women should not breastfeed or store breastmilk for use during niraparib treatment and for 30 days after receiving the final dose of study treatment).
研究组 & 干预措施
Participants receiving niraparib
Participants will receive niraparib once a day, continuously throughout each 90-day cycle until one of the following occurs: disease progression, unacceptable toxicity, initiation of new anticancer therapy that was not part of the parent study, withdrawal of consent, discontinuation at the discretion of the Investigator, noncompliance with protocol, death, or discontinuation for any other reason. The doses provided in this long-term treatment extension study will be those defined in the parent study for each enrolled participant. The starting dose of niraparib will be the same as the assigned dose and regimen that were given in the parent study.
干预措施: Niraparib (Drug)
结局指标
主要结局
Number of participants with clinically significant changes in Eastern Co-operative Oncology Group (ECOG) performance status
时间窗: Up to 5 years
The performance status will be assessed using ECOG scale, where Grade 0 (fully active), Grade 1 (restricted in physically strenuous activity), Grade 2 (ambulatory and capable of all self-care), Grade 3 (capable of only limited self-care) and Grade 4 (completely disabled). Number of participants with clinically significant changes in ECOG performance status will be summarized.
Number of participants with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI)
时间窗: Up to 5 years
AEs, SAEs and AESI will be collected.
Number of participants with clinically significant changes in vital signs
时间窗: Up to 5 years
Number of participants with clinically significant changes in vital signs will be assessed.
Number of participants with clinically significant changes in physical examination
时间窗: Up to 5 years
Number of participants with clinically significant changes in physical examination will be assessed.
Number of participants with use of concomitant medications
时间窗: Up to 5 years
Number of participants using concomitant medications will be assessed.
Number of participants with clinically significant changes in hematology and clinical chemistry parameters
时间窗: Up to 5 years
Blood samples will be collected for the analysis of hematology and clinical chemistry parameters.
次要结局
未报告次要终点